Key clinical point: Patients with various types of psoriasis and psoriatic arthritis tolerated multiple interleukin-17 and IL-23 inhibitors.
Major finding: In a pooled analysis of all treatments, the proportion of patients with any adverse events after 12, 16, 24, and 52 weeks was 0.57, 0.52, 0.72, and 0.81, respectively.
Study details: The data come from a meta-analysis of 43 studies including short-and long-term treatments.
Disclosures: The lead author disclosed serving as an honorary speaker for Eli Lilly; other coauthors disclosed relationships with multiple companies, and two authors reported no conflict of interest. No funding sources for the study were listed .
Loft ND et al. J Eur Acad Dermatol Venereol. 2019 Nov 13. doi: 10.1111/jdv.16073.